Ganeden scores patent for probiotic coffee, tea, cereal

Ganeden scores patent for probiotic coffee, tea, cereal

New U.S. patent covers all Bacillus coagulans including GanedenBC30.

Ganeden Biotech, a recognized world leader in the manufacturing and marketing of probiotics, announced the issuance of a United States patent that covers the use of all Bacillus coagulans in all coffee, tea and cereal.

The issuance of patent #US 8,697,055 B2 protects the use of all Bacillus coagulans probiotic strains including GanedenBC30 in coffee, tea and cereal applications. “Our patent attorneys at Mintz Levin continue to provide superior legal counsel that strengthens our market position,” said David Keller, Ganeden Biotech vice president of scientific operations.

The probiotic industry is growing rapidly, with no indication that it will be slowing down anytime soon; by 2015 the market is expected to reach $31.1 billion globally, with about 90 percent of that from the sale of functional foods and beverages. In addition, consumer awareness continues to increase with over 80 percent of consumers associating probiotics with a health benefit.

Ganeden Biotech’s goal is to make probiotics available in every-day food so that consumers don’t have to take another pill. Coffee, tea and cereal are a big part of that.

Spore-forming probiotic organisms such as GanedenBC30 are the only probiotics that have the ability to withstand harsh manufacturing processes, especially those required to make hot tea, coffee and cereal. The effectiveness of these organisms can be linked to its naturally occurring layer of organic material (spore), which protects the genetic core of the bacteria throughout the manufacturing process and the transit in to the gut. Non-spore forming probiotics, such as Lactobacillus and Bifidobacterium, are unable to form this protective layer, making them much more vulnerable to manufacturing conditions.

“This patent goes a long way toward supporting our partners in their quest to launch new brands, and revolutionize existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.” 


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.